Equities

Vitura Health Ltd

Vitura Health Ltd

Actions
  • Price (EUR)0.0515
  • Today's Change0.001 / 0.98%
  • Shares traded--
  • 1 Year change-71.39%
  • Beta--
Data delayed at least 15 minutes, as of Nov 22 2024 07:11 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Vitura Health Limited is a diversified digital health company that operates various businesses via its subsidiaries CanView, Doctors on Demand, Cortexa, CDA Clinics, Cannadoc, BHC and Adaya. It consists of Medical segment involving the sale and distribution of medicinal cannabis products; Clinics segment involving the operation of medicinal cannabis clinics, and Consumer segment involving the sale of consumer (non-medical) products in both Australia and Asia. Burleigh Heads Cannabis operates the prescriber, patient, pharmacy and supplier online platform, CanView, which sells and distributes 350+ therapeutic products and device stock-keeping units (SKUs) within Australia from medicinal cannabis producers. It also owns Doctors on Demand Pty Ltd, a telehealth platform business that provides primary health solutions. It owns 75.5% Cannadoc Health Pty Ltd, a medicinal cannabis clinic business that undertakes telehealth consultations with patients seeking access to medicinal cannabis.

  • Revenue in AUD (TTM)123.87m
  • Net income in AUD3.51m
  • Incorporated2018
  • Employees119.00
  • Location
    Vitura Health LtdSuite 8Level 3, 299 Toorak Road, South YarraMelbourne 3141AustraliaAUS
  • Phone+61 30079-9491
  • Websitehttps://www.vitura.com.au/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.